Aster DM Healthcare profit and loss

Latest FY26

Revenue: ₹4,643cr+12.2% on FY25
EBITDA: ₹901cr+17.9% on FY25
Net profit: ₹427cr−92.1% on FY25
EPS: ₹7.53−93.0% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Expenses
	4,876	4,643	4,138	3,699	11,933	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	129	126	148	24.9	78.3
	5,005	4,769	4,287	3,724	12,011
	1,101	1,048	920	928	3,812
	−7.4	1.2	18.2	−11.6	−280
	895	848	760	676	3,965
	123	123	124	110	329
	270	264	249	220	780
	1,929	1,845	1,675	1,529	2,871
	4,312	4,129	3,747	3,451	11,477
	958	901	765	578	1,565
	688	637	516	358	785
Profit
	694	639	540	273	534
	−143	−32.7	−50.1	0.0	0.0
	551	607	490	273	534
	199	186	126	32.4	85.8
	−50.5	−43.4	8.6	24.1	−26.2
	149	143	134	56.5	59.6
	−39.7	−37.0	−18.9	−11.3	1.2
	363	427	5,408	212	475
	402	464	356	216	474
	0.0	0.0	5,071	6.9	0.0
	0.9	0.4	−2.1	46.4	199
	364	427	5,406	258	674
	319	388	5,378	129	425
	44.1	39.0	30.1	82.3	50.6
Per share
	₹6.18	₹7.53	₹107.98	₹2.60	₹8.55
	₹6.17	₹7.52	₹107.85	₹2.60	₹8.54
Revenue detail — as filed
	—	0.0	0.0	28.2	0.0
Continuing & discontinued operations
	0.0	0.0	5,071	69.1	0.0
	0.0	0.0	0.0	62.2	0.0
Other comprehensive income — detail
	0.9	0.4	−2.1	—	—
	—	−0.2	−3.1	13.9	37.5
	—	−0.1	−0.8	—	—
	—	—	—	1.5	−0.0
	1.4	0.7	0.3	44.2	235
	0.4	0.2	0.1	—	—
	—	—	—	10.2	73.3
	320	389	5,376	172	599
	44.1	38.9	30.0	86.1	75.6
Per share — as-filed variants
	₹6.18	₹7.53	₹6.16	₹3.60	₹8.55
	₹6.17	₹7.52	₹6.15	₹3.60	₹8.54
	₹0.00	₹0.00	₹101.82	−₹1.00	₹0.00
	₹0.00	₹0.00	₹101.70	−₹1.00	₹0.00
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	3,783	3,594	3,200	2,783	8,401
	77.6%	77.4%	77.3%	75.2%	70.4%
Adjusted (ex-exceptional items) — derived
	694	639	540	273	534
	−143	−32.7	−50.1	0.0	0.0
	467	452	5,444	212	475
	₹7.96	₹7.97	₹108.71	₹2.60	₹8.55

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

ASTERDM₹679.20

Aster DM Healthcare Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersAPOLLOHOSP MAXHEALTH KIMS COHANCE WOCKPHARMA SYNGENE GLAND LALPATHLABMcap ₹35,191 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Revenue from Operations	11,932.9	3,698.9	4,138.5	4,643.2	4,876.0
Other Income	78.3	24.9	148.2	125.6	129.5
Total Income	12,011.1	3,723.8	4,286.7	4,768.8	5,005.5
Expenses
+ Purchases of Stock-in-Trade	3,811.8	927.5	920.2	1,047.6	1,100.8
+ Changes in Inventories	-279.9	-11.6	18.2	1.2	-7.4
+ Employee Benefit Expense	3,965.2	675.9	760.4	848.1	895.5
+ Finance Costs	329.2	110.3	123.8	123.0	123.4
+ Depreciation & Amortisation	780.4	220.0	248.8	264.3	270.3
+ Other Expenses	2,870.6	1,529.2	1,675.2	1,845.3	1,929.1
Total Expenses	11,477.3	3,451.2	3,746.6	4,129.4	4,311.8
EBITDA	1,565.3	578.0	764.5	901.0	958.0
EBIT	784.8	358.0	515.7	636.8	687.7
Profit
PBT before Exceptional Items	533.9	272.5	540.1	639.4	693.7
+ Exceptional Items	0.0	0.0	-50.1	-32.7	-142.7
Pretax Income	533.9	272.5	490.0	606.7	551.0
+ Current Tax	85.8	32.4	125.7	186.0	199.0
+ Deferred Tax	-26.2	24.1	8.6	-43.4	-50.5
Tax Expense	59.6	56.5	134.4	142.6	148.5
+ Share of Associates & JVs	1.2	-11.3	-18.9	-37.0	-39.7
Net Income	475.5	211.6	5,407.9	427.1	362.8
+ Net Income — Continuing Ops	474.3	216.0	355.6	464.1	402.5
+ Net Income — Discontinued Ops	0.0	6.9	5,071.2	0.0	0.0
+ Other Comprehensive Income	199.0	46.4	-2.1	0.4	0.9
Total Comprehensive Income	674.4	258.0	5,405.8	427.5	363.7
Net Income to Common	424.9	129.3	5,377.8	388.1	318.7
Minority Interest	50.6	82.3	30.1	39.0	44.1
Per Share
Basic EPS	8.55	2.60	107.98	7.53	6.18
Diluted EPS	8.54	2.60	107.85	7.52	6.17
Revenue Detail — as filed
+ Share of P&L — Partnership Firms / LLPs	0.0	28.2	0.0	0.0	—
Continuing & Discontinued Operations
+ Discontinued Operations — before Tax	0.0	69.1	5,071.2	0.0	0.0
+ Tax — Discontinued Operations	0.0	62.2	0.0	0.0	0.0
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	-2.1	0.4	0.9
+ Items NOT to be Reclassified to P&L	37.5	13.9	-3.1	-0.2	—
+ Tax on Items NOT to be Reclassified	—	—	-0.8	-0.1	—
+ Tax on Items NOT to be Reclassified — alt tag	-0.0	1.5	—	—	—
+ Items to be Reclassified to P&L	234.6	44.2	0.3	0.7	1.4
+ Tax on Items to be Reclassified	—	—	0.1	0.2	0.4
+ Tax on Items to be Reclassified — alt tag	73.3	10.2	—	—	—
Comprehensive Income — Owners of Parent	598.8	171.9	5,375.8	388.5	319.6
Comprehensive Income — Non-controlling Interests	75.6	86.1	30.0	38.9	44.1
Per Share — as-filed variants
Basic EPS — Continuing Operations	8.55	3.60	6.16	7.53	6.18
Diluted EPS — Continuing Operations	8.54	3.60	6.15	7.52	6.17
Basic EPS — Discontinued Operations	0.00	-1.00	101.82	0.00	0.00
Diluted EPS — Discontinued Operations	0.00	-1.00	101.70	0.00	0.00
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	8,401.1	2,783.0	3,200.1	3,594.4	3,782.6
Gross Margin %	70.40	75.24	77.33	77.41	77.58
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	533.9	272.5	540.1	639.4	693.7
− Exceptional Items (reconciliation)	0.0	0.0	-50.1	-32.7	-142.7
Net Income Adj (tax-effected)	475.5	211.6	5,444.3	452.1	467.1
EPS Adj	8.55	2.60	108.71	7.97	7.96
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	10.00	10.00	10.00	10.00	10.00
Paid Up Equity Capital	499.5	499.5	499.5	518.1	518.1

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.